Cell & Gene: The Podcast
Cell & Gene: The Podcast
Reimagining Solid Tumor Immunotherapy Through Engineered Tregs with CoRegen's Dr. Sonal Gupta
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
We love to hear from our listeners. Send us a message.
In Episode 135 of Cell & Gene: The Podcast, Host Erin Harris talks to Sonal Gupta, MD, PhD, Chief Medical Officer of CoRegen, about the company's novel approach to treating solid tumors by engineering regulatory T cells (Tregs) rather than conventional effector immune cells. Dr. Gupta explains how CoRegen's investigational cell therapy, CRG150, targets the upstream regulator SRC3 to simultaneously influence multiple immune checkpoint pathways. She also discusses the scientific rationale behind the platform, the transition into first-in-human clinical studies, the biomarkers and translational questions the company hopes to answer, and why manufacturing, CDMO selection, and chain-of-identity capabilities are foundational to the future success of autologous cell therapies.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
